YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Small cell lung cancer (SCLC) comprises distinct subtypes (SCLC-A, SCLC-N, SCLC-Y, SCLC-P) defined by specific transcription factors.
• The clinical and biological significance of these SCLC subtypes requires further elucidation.

Purpose of the Study:

• To establish the clinical and biological significance of the four newly described SCLC subtypes.
• To investigate the association between SCLC subtypes and patient prognosis.

Main Methods:

• Generated RNA sequencing and immunohistochemistry data from SCLC tumor samples and cell lines.
• Classified SCLC cases into subtypes based on transcription factor expression.
• Performed gene set enrichment analysis to identify differentially expressed genes in SCLC survival outliers.

Main Results:

• Successfully classified 71.8% of SCLC and 18.5% of carcinoid cases into the four SCLC subtypes.
• Identified an "inflamed" phenotype characterized by interferon-γ response genes, HLA, and T-cell receptor genes in long-term SCLC survivors.
• The SCLC-Y subtype, associated with YAP1 expression, showed a higher prevalence in limited-stage SCLC, indicating a good prognosis.

Conclusions:

• SCLC subtyping based on transcriptional signaling holds significant clinical relevance.
• The inflamed phenotype observed in the SCLC-Y subtype is associated with a favorable prognosis in SCLC.